Detailed Information on Publication Record
2020
Anti-Mullerian hormone as an ovarian reserve marker in women with the most frequent muscular dystrophies
PARMOVÁ, Olesja, Eva VLČKOVÁ, Monika HULOVÁ, Livie MENSOVA, Igor CRHA et. al.Basic information
Original name
Anti-Mullerian hormone as an ovarian reserve marker in women with the most frequent muscular dystrophies
Authors
PARMOVÁ, Olesja (203 Czech Republic, belonging to the institution), Eva VLČKOVÁ (203 Czech Republic, belonging to the institution), Monika HULOVÁ (203 Czech Republic, belonging to the institution), Livie MENSOVA (203 Czech Republic), Igor CRHA (203 Czech Republic, belonging to the institution), Petra STRÁDALOVÁ (203 Czech Republic, belonging to the institution), Eva KRALICKOVA (203 Czech Republic), Lenka JUŘÍKOVÁ (203 Czech Republic, belonging to the institution), Martina PODBORSKÁ (203 Czech Republic), Radim MAZANEC (203 Czech Republic, belonging to the institution), Ladislav DUŠEK (203 Czech Republic, belonging to the institution), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Josef BEDNAŘÍK (203 Czech Republic, belonging to the institution), Stanislav VOHÁŇKA (203 Czech Republic, belonging to the institution) and Iva ŠROTOVÁ (203 Czech Republic, guarantor, belonging to the institution)
Edition
Medicine, Philadelphia, Lippincott Williams & Wilkins, 2020, 0025-7974
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30218 General and internal medicine
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 1.889
RIV identification code
RIV/00216224:14110/20:00116134
Organization unit
Faculty of Medicine
UT WoS
000549892300041
Keywords in English
anti-Mullerian hormone; fertility; muscular dystrophy; myotonic dystrophy; ovarian reserve
Tags
International impact, Reviewed
Změněno: 3/3/2021 15:44, Mgr. Tereza Miškechová
Abstract
V originále
Some muscular dystrophies may have a negative impact on fertility. A decreased ovarian reserve is 1 of the factors assumed to be involved in fertility impairment. AMH (anti-Mullerian hormone) is currently considered the best measure of ovarian reserve. A total of 21 females with myotonic dystrophy type 1 (MD1), 25 females with myotonic dystrophy type 2 (MD2), 12 females with facioscapulohumeral muscular dystrophy (FSHD), 12 female carriers of Duchenne muscular dystrophy mutations (cDMD) and 86 age-matched healthy controls of reproductive age (range 18 - 44 years) were included in this case control study. An enzymatically amplified 2-site immunoassay was used to measure serum AMH level. The MD1 group shows a significant decrease of AMH values (median 0.7ng/mL; range 0 - 4.9ng/mL) compared with age-matched healthy controls (P<.01). AMH levels were similar between patients and controls in terms of females with MD2 (P=.98), FSHD (P=.55) and cDMD (P=.60). This study suggests decreased ovarian reserve in women with MD1, but not in MD2, FSHD and cDMD.
Links
MUNI/A/1072/2017, interní kód MU |
| ||
MUNI/A/1325/2019, interní kód MU |
|